Zeitschrift für Gastroenterologie, Table of Contents Z Gastroenterol 2024; 62(06): 978-982DOI: 10.1055/a-2322-6582 Mitteilungen der DGVS Themen – Stellungnahme zur Nutzenbewertung von Durvalumab (neues Anwendungsgebiet, hepatozelluläres Karzinom, Erstlinie Monotherapie) vom 05. April 2024 Recommend Article Abstract Buy Article Full Text References Literatur 1 Koch Institut: Krebs in Deutschland. Gesellschaft der epidemiologischen Krebsregister in Deutschland/Robert. 2018 http://www.gekid.de/Atlas/CurrentVersion/atlas.html 2 Siegel RL, Miller KD, Jemal A. Cancer statistics. CA Cancer J Clin 2018; 68: 7-30 3 AWMF S3-Leitlinie H Diagnostik und Therapie des hepatozellulären Karzinoms. 2023 4 Llovet JM, Ricci S, Mazzaferro V. et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008; 359: 378-390 5 Cheng AL, Kang YK, Lin DY. et al. Sunitinib versus sorafenib in advanced hepatocellular cancer: Results of a randomized phase III trial. J Clin Oncol 2013; 31: 4067-4075 6 Kudo M, Finn RS, Qin S. et al. A Randomised Phase 3 trial of lenvatinib vs. sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma. Lancet 2018; 391: 1163-1173 7 Finn RS, Qin S, Ikeda M. et al. Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma. N Engl J Med 2020; 382: 1894-1905 8 Cheng AL, Qin S, Ikeda M. et al. Updated efficacy and safety data from IMbrave150: Atezolizumab plus bevacizumab vs. sorafenib for unresectable hepatocellular carcinoma. J Hepatol 2022; 76: 862-873 9 Abou-Alfa G, Lau G, Kudo M. et al. Tremelimumab plus durvalumab in unresectable hepatocellular carcinoma. NEJM Evid 2022; 1 (08) 10 Sangro B, Chan SL, Kelley RK. et al. Four-year overall survival update from the phase III HIMALAYA study of tremelimumab plus durvalumab in unresectable hepatocellular carcinoma. Ann Oncol 2024; 11 ESMO-MCBS Scorecards | ESMO.
